The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Objective There is growing evidence showing a relation between depression, metabolic syndrome, diabetes, cardiovascular disease (1), serum lipid profile (2,3) and body weight (4), as well as the effects of some of the antidepressant medications on these various conditions and profiles.
The aim of the study is to examine the influence of antidepressant medications on the metabolic profiles (5) of patients suffering from Major Depressive Disorder (MDD).
Group of patients:
30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
Research Design and Methods:
Research duration will be 8 weeks. Patients meeting the inclusion criteria will be recruited after being diagnosed with MDD and having undertaken the HDRS. A follow-up HDRS will be taken at weeks 4 and 8. The psychiatric evaluation will be held by a resident in psychiatry.
The following metabolic parameters will be examined at base-line and at the end of the 8 weeks:
Weight, height, waist circumference, body mass index (BMI: (Weight in Kg/(Height in meters)2), sitting blood pressure (after 3 minutes of sitting).
Serum lipid profile (performed in Ziv hospital's chemistry lab): Low density lipoprotein cholesterol, High density Lipoprotein cholesterol, Triglycerides, Total cholesterol, Apolipoprotein level (Apo AI, Apo B, Apo E, Apo AII).
Fasting glucose and insulin blood levels, in order to evaluate insulin-release and resistance, according to the following formulas:
Insulin Resistance:
HOMA IR=Fasting glucose (mg/dL)x Fasting insulin (mmol/L)/405
Insulin Release:
HOMA-β={360xfasting insulin (mmol/L)}/{glucose(mg/dL)-63} Serum oxidative stress parameters according to the F2-Isoprostane kit will be measured.
Malonylaialdehyde (MDA) content in serum will be analyzed by the thiobarbituric acid reactive substances assay, which measures malondialdehyde equivalent (13). Conjugated dienes will be measured at 234nm (14, 15).
| Condition |
|---|
|
Major Depressive Disorder |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder |
- the influence of antidepressant medications on the metabolic profiles (5) of patients suffering from Major Depressive Disorder. [ Time Frame: 8 WEEKS ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 30 |
| Study Start Date: | May 2012 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
30 Patients with MDD.
30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
Inclusion Criteria:
- MDD diagnosed patients with a Hamilton Depression Rating Scale (HDRS) score of at least 18 points. Patients not treated with medications or such that had shown resistance to treatment, and were therefore assigned for drug replacement.
- Patients on stable therapy for hypertension, diabetes mellitus, hypothyroidism, dyslipidemia and / or weight lowering medications
Exclusion Criteria:
- Patients receiving antipsychotic treatment as well as patients on mood stabilizers will be excluded.
- Patients with uncontrolled diabetes mellitus, uncontrolled thyroid functioning, or uncontrolled hypertension, as well as patients who regularly consume alcohol will be excluded.
- Patients with uncontrolled malignancy are excluded as well.
Contacts and Locations| Contact: Osamah Hussein, MD | osama.h@ziv.health.gov.il |
| Israel | |
| Ziv MC | Recruiting |
| Safed, Israel, 13110 | |
| Contact: Osamah Hussein, MD | |
| Principal Investigator: Osamah Hussein, MD | |
| Principal Investigator: | Osamah Hussein, MD | Ziv Medical Center |
More Information
No publications provided
| Responsible Party: | Osamah Hussein, Osamah Hussein, MD, Ziv Hospital |
| ClinicalTrials.gov Identifier: | NCT01418638 History of Changes |
| Other Study ID Numbers: | 01-11 ZIV |
| Study First Received: | August 16, 2011 |
| Last Updated: | February 19, 2013 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by Ziv Hospital:
|
Major Depressive Disorder Antidepressants |
Additional relevant MeSH terms:
|
Depressive Disorder Depression Depressive Disorder, Major Mood Disorders Mental Disorders Behavioral Symptoms |
Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013